Hospitals Immune Response Pharmaceuticals Pharmacy 
The Pharma Data
DECEMBER 29, 2020
29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.
The Pharma Data
DECEMBER 17, 2020
17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. ,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
APRIL 14, 2023
Melissa M Hudson, MD – Joseph H Burchenal Award for Outstanding Achievement in Clinical Cancer Research Hudson is a faculty member, Director of the Cancer Survivorship Division, Associate Director, Population Sciences, and The Charles E Williams Endowed Chair of Oncology-Cancer Survivorship at St Jude Children’s Research Hospital.
The Pharma Data
OCTOBER 28, 2020
Regeneron Pharmaceuticals, Inc. REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits). The Phase 3 portion of this trial continues in non-hospitalized patients. Yancopoulos , M.D., combined dose groups; 6.5%
The Pharma Data
NOVEMBER 20, 2020
November 21, 2020 – Regeneron Pharmaceuticals, Inc. The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.
The Pharma Data
NOVEMBER 21, 2020
Regeneron Pharmaceuticals, Inc. The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.
Codon
FEBRUARY 13, 2024
Regulators traditionally want to see a single, stable, well-characterized drug before giving the green light for it to be tested in a clinical trial, not dozens of different viruses; let alone ones that are best found in unappealing places like sewage , hospital waste, or bird poop. Phage therapies are sold at a pharmacy in Georgia.
Expert insights. Personalized for you.
52 
Let's personalize your content